Xyall secures €6 million Series B financing to spearhead commercialization of its automated tissue dissector
Xyall, a global innovator in molecular pathology, has attracted a Series B investment of €6 million to accelerate commercialization of its Tissector High Throughput and Tissector Table Top systems.